G1 Therapeutics (NASDAQ:GTHX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday.
Other research analysts have also recently issued reports about the company. BTIG Research assumed coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $31.40.
G1 Therapeutics (GTHX) opened at $25.35 on Tuesday. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67.
In related news, insider Rajesh Malik sold 3,776 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total transaction of $86,696.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $20.01, for a total value of $4,002,000.00. The disclosure for this sale can be found here. Insiders have sold 545,932 shares of company stock valued at $10,848,385 over the last ninety days.
A number of hedge funds and other institutional investors have recently modified their holdings of GTHX. American International Group Inc. acquired a new position in G1 Therapeutics during the third quarter valued at approximately $130,000. California State Teachers Retirement System acquired a new position in G1 Therapeutics during the third quarter valued at approximately $319,000. Schwab Charles Investment Management Inc. acquired a new position in G1 Therapeutics during the third quarter valued at approximately $364,000. Bank of New York Mellon Corp acquired a new position in G1 Therapeutics during the third quarter valued at approximately $568,000. Finally, Alps Advisors Inc. boosted its position in G1 Therapeutics by 9.1% during the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after purchasing an additional 2,317 shares during the last quarter. 43.25% of the stock is owned by hedge funds and other institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.